Phosphodiesterase-5 inhibitors and their hemodynamic effects

Current Hypertension Reports

Volumn 8, Issue 4, 2006, Pages 345-351

  Prisant, L Michael ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DOXAZOSIN; ENALAPRIL; GLYCERYL TRINITRATE; ISOSORBIDE MONONITRATE; NIFEDIPINE; NITRIC ACID DERIVATIVE; PHOSPHODIESTERASE V; SILDENAFIL; TADALAFIL; TAMSULOSIN; TERAZOSIN; THIAZIDE DIURETIC AGENT; VARDENAFIL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; ERECTILE DYSFUNCTION; HEMODYNAMICS; HUMAN; HYPERTENSION; LOW DRUG DOSE; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PROSTATE HYPERTROPHY; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-GMP PHOSPHODIESTERASES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARBOLINES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; HUMANS; HYPERTENSION; HYPOTENSION; IMIDAZOLES; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONES; TRIAZINES; VASCULAR RESISTANCE;

EID: 33747597607     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0075-y     Document Type: Review

References (39)

1. Solursh DS, Ernst JL, Lewis RW, et al.: The human sexuality education of physicians in North American medical schools. Int J Impot Res 2003, 15(Suppl 5):S41-S45.
2. Prisant LM: Sexual dysfunction and hypertension. In Hypertension Primer, 3rd edn. Edited by Izzo JL, Black HR. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:470-472.
3. Loebl D, Fain H, Prisant LM: Relationship of arterial elasticity and erectile dysfunction in hypertensive men. Am J Hypertens 2004, 17(5 Suppl):S16.
4. Prisant LM, Weir MR, Frishman WH, et al.: Self reported sexual dysfunction in men and women treated with bisoprolol, hydrochlorothiazide, enalapril, amlodipine, placebo, or bisoprolol/ hydrochlorothiazide. J Clin Hypertens (Greenwich) 1999,1:22-126.
5. Prisant LM, Carr AA, Bottini PB, et al.: Sexual dysfunction with antihypertensive drugs. Arch Intern Med 1994, 154:730-736.
6. Grimm RH Jr, Grandits GA, Prineas RJ, et al.: Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997, 29(1 Pt 1):8-14.
7. Thompson IM, Tangen CM, Goodman PJ, et al.: Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005, 294:2996-3002.
8. Katzenstein L: Viagra (sildenafil citrate): The Remarkable Story of the Discovery and Launch. New York, NY: Medical Information Press; 2001.
9. Rajfer J, Aronson WJ, Bush PA, et al.: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992, 326:90-94.
10. Boolell M, Allen MJ, Ballard SA, et al.: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996, 8:47-52.
11. Wallis RM, Corbin JD, Francis SH, et al.: Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999, 83:3C-12C.
12. Goldstein I, Lue TF, Padma-Nathan H, et al.: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998,338:1397-1404.
13. Jackson G, Keltai M, Csanady M, et al.: Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction. J Sex Med 2005, 2:407-414.
14. Webb DJ, Freestone S, Allen MJ, et al.: Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999, 83:21C-28C.
15. Webb DJ, Muirhead GJ, Wulff M, et al.: Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000, 36:25-31.
16. Cheitlin MD, Hurter AM, Jr., Brindis RG, et al.: ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999, 33(1):273-282.
17. Zusman RM, Prisant LM, Brown MJ: Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J Hypertens 2000, 18:1865-1869.
18. Kloner RA, Brown M, Prisant LM, et al.: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 2001, 14:70-73.
19. Pickering TG, Shepherd AM, Puddey I, et al.: Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens 2004, 17(12 Pt 1):1135-1142.
20. Vardi Y, Klein L, Nassar S, et al.: Effects of sildenafil citrate (Viagra) on blood pressure in normotensive and hypertensive men. Urology 2002, 59:747-752.
21. Prescribing information for Viagra (sildenafil citrate) tablets. http://www.fda.gov/cder/foi/tabet/2005/020895sO21lbl.pdf. Accessed February 5, 2006.
22. Mahmud A, Hennessy M, Feely J: Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens 2001, 15:707-713.
23. Vlachopoulos C, Hirata K, O'Rourke MF: Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med 2003, 8:243-248.
24. Ghofrani HA, Voswinckel R, Reichenberger F, et al.: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004, 44:1488-1496.
25. Thadani U, Smith W, Nash S, et al.: The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002, 40:2006-2012.
26. Prescribing information for Levitra (vardenafil HCl) tablets. http://www.fda.gov/cder/foi/label/2005/0214OOsOO41bl.pdf. Accessed February 5, 2006.
27. Hellstrom WJG, Gittelman M, Karlin G, et al.: Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002, 23:763-771.
28. Pomara G, Morelli G, Pomara S, et al.: Cardiovascular parameter changes in patients with erectile dysfunction using PDE-5 inhibitors: a study with sildenafil and vardenafil. J Androl 2004, 25:625-629.
29. van Ahlen H, Wahle K, Kupper W, et al.; Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005, 2:856-864.
30. Auerbach SM, Gittelman M, Mazzu A, et al.: Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004, 64:998-1003; discussion 1003-1004.
31. Emmick JT, Stuewe SR, Mitchell M: Overview of the cardiovascular effects of tadalafil. Eur Heart J 2002, 4(Suppl H):H32-H47.
32. Kloner RA, Hutter AM, Emmick JT, et al.: Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003, 42:1855-1860.
33. Kloner RA, Sadovsky R, Johnson EG, et al.: Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. Int J Impot Res 2005, 17:450-454.
34. Kloner RA, Mitchell M, Emmick JT: Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003, 92:47M-57M.
35. Kloner RA, Jackson G, Emmick JT, et al.: Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004, 172:1935-1940.
36. Prescribing information for Cialis (tadalafil) tablets. http://www.fda.gov/cder/foi/label/2005/021368sOO6lbl.pdf. Accessed February 5, 2006.
37. Kloner RA: Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004, 110:3149-3155.
38. Kloner RA: Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005, 96:42M-46M.
39. Kostis JB, Jackson G, Rosen R, et al.: Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005, 96:313-321.